Cost-Effectiveness of an Adjuvanted Hepatitis B Vaccine (HEPLISAV-B) in Patients With Inflammatory Bowel Disease.
Juan E CorralJoshua Y KwonFreddy CalderaSurakit PungpapongAaron C SpauldingBijan J BorahJames P MoriartyFrancis A FarrayePublished in: Crohn's & colitis 360 (2020)
HEPLISAV-B is cost-effective over Engerix-B in patients receiving immunosuppressive therapy for IBD. Benefits increase with population aging and lower costs of vaccines. We advocate measuring levels of HBV antibodies in patients with IBD and favor adjuvanted vaccines when vaccination is needed.